258 related articles for article (PubMed ID: 31619740)
41. Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population.
Senda N; Kawaguchi-Sakita N; Kawashima M; Inagaki-Kawata Y; Yoshida K; Takada M; Kataoka M; Torii M; Nishimura T; Kawaguchi K; Suzuki E; Kataoka Y; Matsumoto Y; Yoshibayashi H; Yamagami K; Tsuyuki S; Takahara S; Yamauchi A; Shinkura N; Kato H; Moriguchi Y; Okamura R; Kan N; Suwa H; Sakata S; Mashima S; Yotsumoto F; Tachibana T; Tanaka M; Togashi K; Haga H; Yamada T; Kosugi S; Inamoto T; Sugimoto M; Ogawa S; Toi M
Cancer Sci; 2021 Aug; 112(8):3338-3348. PubMed ID: 34036661
[TBL] [Abstract][Full Text] [Related]
42. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
[TBL] [Abstract][Full Text] [Related]
43. Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China.
Deng M; Chen HH; Zhu X; Luo M; Zhang K; Xu CJ; Hu KM; Cheng P; Zhou JJ; Zheng S; Chen YD
Int J Cancer; 2019 Sep; 145(6):1517-1528. PubMed ID: 30720863
[TBL] [Abstract][Full Text] [Related]
44. Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.
Park JS; Lee ST; Nam EJ; Han JW; Lee JY; Kim J; Kim TI; Park HS
BMC Cancer; 2018 Jan; 18(1):83. PubMed ID: 29338689
[TBL] [Abstract][Full Text] [Related]
45. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N
Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409
[TBL] [Abstract][Full Text] [Related]
46. BRCA and PALB2 mutations in a cohort of male breast cancer with one bilateral case.
Vietri MT; Caliendo G; D'Elia G; Resse M; Casamassimi A; Minucci PB; Cioffi M; Molinari AM
Eur J Med Genet; 2020 Jun; 63(6):103883. PubMed ID: 32058061
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan.
Rashid MU; Khan FA; Muhammad N; Loya A; Hamann U
Cancer Res Treat; 2019 Jul; 51(3):992-1000. PubMed ID: 30309218
[TBL] [Abstract][Full Text] [Related]
48. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
[TBL] [Abstract][Full Text] [Related]
49. PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
Zhang F; Ma J; Wu J; Ye L; Cai H; Xia B; Yu X
Curr Biol; 2009 Mar; 19(6):524-9. PubMed ID: 19268590
[TBL] [Abstract][Full Text] [Related]
50. Ethnicity-specific BRCA1, BRCA2, PALB2, and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus.
Sokolenko AP; Bakaeva EK; Venina AR; Kuligina ES; Romanko AA; Aleksakhina SN; Belysheva YV; Belogubova EV; Stepanov IA; Zaitseva OA; Yatsuk OS; Togo AV; Khamgokov ZM; Kadyrova AO; Pirmagomedov AS; Bolieva MB; Epkhiev AA; Tsutsaev AK; Chakhieva MD; Khabrieva KM; Khabriev IM; Murachuev MA; Buttaeva BN; Baboshkina LS; Bayramkulova FI; Katchiev IR; Alieva LK; Raskin GA; Orlov SV; Khachmamuk ZK; Levonyan KR; Gichko DM; Kirtbaya DV; Degtyariov AM; Sultanova LV; Musayeva HS; Belyaev AM; Imyanitov EN
Breast Cancer Res Treat; 2024 Jan; 203(2):307-315. PubMed ID: 37851290
[TBL] [Abstract][Full Text] [Related]
51. Pan-cancer landscape of homologous recombination deficiency.
Nguyen L; W M Martens J; Van Hoeck A; Cuppen E
Nat Commun; 2020 Nov; 11(1):5584. PubMed ID: 33149131
[TBL] [Abstract][Full Text] [Related]
52. Frequent Abnormal Pancreas Imaging in Patients With Pathogenic ATM, BRCA1, BRCA2, and PALB2 Breast Cancer Susceptibility Variants.
Lucas AL; Fu Y; Labiner AJ; Dimaio CJ; Sethi A; Kastrinos F
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2686-2688.e2. PubMed ID: 36087707
[No Abstract] [Full Text] [Related]
53. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
Foo TK; Tischkowitz M; Simhadri S; Boshari T; Zayed N; Burke KA; Berman SH; Blecua P; Riaz N; Huo Y; Ding YC; Neuhausen SL; Weigelt B; Reis-Filho JS; Foulkes WD; Xia B
Oncogene; 2017 Jul; 36(29):4161-4170. PubMed ID: 28319063
[TBL] [Abstract][Full Text] [Related]
54. Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer.
Kimura H; Mizuno K; Shiota M; Narita S; Terada N; Fujimoto N; Ogura K; Hatano S; Iwasaki Y; Hakozaki N; Ishitoya S; Sumiyoshi T; Goto T; Kobayashi T; Nakagawa H; Kamoto T; Eto M; Habuchi T; Ogawa O; Momozawa Y; Akamatsu S
Br J Cancer; 2022 Nov; 127(9):1680-1690. PubMed ID: 35986085
[TBL] [Abstract][Full Text] [Related]
55. [PALB2, a major susceptibility gene for breast cancer].
Piffer A; Luporsi E; Mathelin C
Gynecol Obstet Fertil Senol; 2018 Nov; 46(10-11):701-705. PubMed ID: 30243941
[TBL] [Abstract][Full Text] [Related]
56. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
[TBL] [Abstract][Full Text] [Related]
57. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
Boddicker NJ; Hu C; Weitzel JN; Kraft P; Nathanson KL; Goldgar DE; Na J; Huang H; Gnanaolivu RD; Larson N; Yussuf A; Yao S; Vachon CM; Trentham-Dietz A; Teras L; Taylor JA; Scott CE; Sandler DP; Pesaran T; Patel AV; Palmer JR; Ong IM; Olson JE; O'Brien K; Neuhausen S; Martinez E; Ma H; Lindstrom S; Le Marchand L; Kooperberg C; Karam R; Hunter DJ; Hodge JM; Haiman C; Gaudet MM; Gao C; LaDuca H; Lacey JV; Dolinsky JS; Chao E; Carter BD; Burnside ES; Bertrand KA; Bernstein L; Auer PW; Ambrosone C; Yadav S; Hart SN; Polley EC; Domchek SM; Couch FJ
J Clin Oncol; 2021 Nov; 39(31):3430-3440. PubMed ID: 34292776
[TBL] [Abstract][Full Text] [Related]
58. Retesting of women who are negative for a
Lerner-Ellis J; Sopik V; Wong A; Lázaro C; Narod SA; Charames GS
J Med Genet; 2020 Jun; 57(6):380-384. PubMed ID: 31784482
[TBL] [Abstract][Full Text] [Related]
59. EUS-based Pancreatic Cancer Surveillance in
Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
[TBL] [Abstract][Full Text] [Related]
60. PALB2: a novel inactivating mutation in a Italian breast cancer family.
Balia C; Sensi E; Lombardi G; Roncella M; Bevilacqua G; Caligo MA
Fam Cancer; 2010 Dec; 9(4):531-6. PubMed ID: 20852946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
